Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 17th Preview)
-
AI drug discovery financing
Isomorphic Labs, the AI-focused drug developer backed by Alphabet, raised $5 billion in a private Series C financing led by Greenoaks and Sequoia Capital, BioPharma Dive reported. The round includes participation from existing investors and new backers including Andreessen Horowitz, following a $2.1 billion Series B announced in May. The company said the financing is intended to move from AI platform development toward bringing medicines into the clinic, with plans to expand into additional biology areas. The size of the round underscores continued investor appetite for “AI-first” drug discovery despite broader tech-market volatility.
-
FDA and oncology: class safety signal in bispecifics
The FDA flagged a potential VEGF-related safety concern in its review of Summit Therapeutics and Akeso’s now-rejected ivonescimab program, according to the companies’ correspondence referenced in a report. The feedback raises questions about the viability of VEGF-linked safety for a broader bispecifics class. The rejection adds another regulatory headwind for developers targeting angiogenesis-linked mechanisms, particularly for next-generation bispecific antibodies that aim to combine immune engagement with tumor vascular signaling.
-
Regulatory approval: rare disease gene therapy
Beren Therapeutics won FDA approval for Lembaz (adrabetadex), a gene-targeting therapy intended for infantile-onset Niemann-Pick disease type C, capping what the report describes as a long development path. The approval marks a new option for a rapidly progressive lysosomal disorder with limited treatments. For investors and clinical teams, the decision also reinforces continued regulatory traction for gene-based therapies targeting inherited metabolic disease—especially where existing standards have not meaningfully altered trajectories.
-
M&A: J&J expands ophthalmology with Ollin Biosciences
Johnson & Johnson agreed to acquire clinical-stage biotech Ollin Biosciences in a deal worth up to $3.325 billion, including milestones, to deepen its ophthalmology pipeline. The acquisition targets additional late-stage and platform-driven capabilities as J&J builds out its eye-care roster. The transaction highlights continued large-pharma willingness to buy clinical-stage assets in ophthalmology, where differentiation and durability of efficacy/safety profiles drive long-term commercial positioning.
-
Phase 3: AML vaccine reduces mortality risk
Sellas Life Sciences said its Phase 3 trial of galinpepimut-S (GPS) in advanced acute myeloid leukemia met the primary endpoint, reducing the risk of death by 41% versus standard treatment, according to the company. The result positions the cancer vaccine strategy as a late-stage contender in AML, a disease where immunotherapy options remain limited. The announcement is expected to sharpen scrutiny on endpoint definitions, subgroup effects, and the durability of survival benefits as regulators and clinicians weigh where a vaccine approach fits alongside evolving AML standards of care.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.